Form 4 for CRL Charles River Laboratories
Accepted 2026-03-04 00:00:00 ET · period of report 2026-03-02 · accession 0001100682-26-000026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | 2026-03-02 | CRL | FOSTER JAMES C | COB, Pres, CEO, Dir | A - Grant | $178.61 | +16.8K | 279.7K | +6% | +$3.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-02 | A | A | 16,796 | $178.61 | 279,693 | D | — | — | (F1) 100% of the unvested restricted stock units vest on March 2, 2028. (F2) Reflects the exempt transfer pursuant to Rule 16a-13 of 9,220 shares from the 2025 GRAT account to direct holdings. |